GREENWICH LIFESCIENCES, INC.

GLSI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-19.4M $-17.4M $-8.9M $-7.8M $-4.6M $-1.9M $-3.4M
Depreciation & Amortization
Depreciation
Amortization
Stock-Based Compensation $6.8M $7.3M $2.4M $1.7M $660.6K $678.0K $194.9K
Net Cash from Operating Activities $-9.9M $-7.3M $-6.5M $-6.2M $-4.3M $-1.2M $-293.3K
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities
Financing Activities
Dividends Paid
Stock Repurchases $7.5M
Net Cash from Financing Activities $12.0M $4.4M $-7.5M $2.8M $29.8M $215.0K
Net Change in Cash $2.1M $-2.9M $-6.5M $-13.7M $-1.5M $28.7M $-78.3K
Free Cash Flow